AZN · Astrazeneca PLC · Webcasts, Transcripts & Audio
$184.02
-0.43 (-0.23%)
At close · Nov 16
Return incl. dividend (before tax)
Q1 2026 earnings call transcript
Market Cap
$285.40B
Shares
1.55B
Volume · Nov 16
1.95M
Avg daily vol (3M)
3.03M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Astrazeneca PLC Webcasts
Earnings calls, investor updates, investor days and conferences for Astrazeneca PLC (AZN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-30
Astrazeneca PLC (AZN) Q3 2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-27
Astrazeneca PLC (AZN) Q2 2026 Earnings Call
Revenue
$15.38B
▲ 6.4% YoY Diluted EPS
$1.61
▲ 2.5% YoY Gross margin
83.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Astrazeneca PLC (AZN) Q1 2026 Earnings Call Transcript
Confident tone
Q1 financial performance
Upcoming launches
Pipeline and R&D
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-10
Astrazeneca PLC (AZN) Q4 2025 Earnings Call Transcript
Confident tone
Pipeline and Phase III catalysts
Geographic diversification
Revenue and financial growth
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Astrazeneca PLC (AZN) Q3 2025 Earnings Call Transcript
Confident tone
Rare Disease and Biopharmaceuticals
Financial performance and guidance
Pipeline and Phase III readouts
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Date not confirmed
Astrazeneca PLC (AZN) Q2 2025 Earnings Call Transcript
Confident tone
Oncology portfolio expansion
Rare disease and C5 franchise
China VBP and Farxiga
Revenue
$14.46B
▲ 11.7% YoY Diluted EPS
$1.57
▼ 36.7% YoY Gross margin
82.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Astrazeneca PLC (AZN) Q1 2025 Earnings Call Transcript
Confident tone
Oncology Performance (Tagrisso, Calquence, Imfinzi)
Tariffs and Manufacturing Footprint
China and Emerging Markets
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Astrazeneca PLC (AZN) Q4 2024 Earnings Call Transcript
Confident tone
2024 financial performance
Gross margin guidance
China business and investigations
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Astrazeneca PLC (AZN) Q3 2024 Earnings Call Transcript
Confident tone
Broad-based revenue growth across regions
U.S. manufacturing and R&D investment
China investigations and business impact
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Astrazeneca PLC (AZN) Q2 2024 Earnings Call Transcript
Confident tone
Revenue and Earnings Growth
China and Emerging Markets
Collaboration Revenue Uncertainty
Revenue
$12.94B
▲ 13.3% YoY Diluted EPS
$2.48
▲ 6% YoY Gross margin
83.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Astrazeneca PLC (AZN) Q1 2024 Earnings Call Transcript
Confident tone
Biopharmaceuticals and respiratory
Organizational structure
Capital allocation and M&A
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Astrazeneca PLC (AZN) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–12 of 12 webcasts
Key facts
CIK
901832
CUSIP
G0593M107
13F (30d)
1094 filings
1075 filers
Visit website
Investor relations